Accenture vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Accenture and AstraZeneca side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1953Accenture

   Arthur Andersen GE feasibility study

   Arthur Andersen's administrative services group, led by Joseph Glickauf, carries out a study for General Electric on computerizing payroll at Appliance Park in Louisville, Kentucky.

3. 1989Accenture

   Andersen Consulting formed

   Arthur Andersen and Andersen Consulting become separate units of Andersen Worldwide Societe Cooperative, with George Shaheen as managing partner and CEO of the consulting unit. The more profitable unit pays the other up to 15% of profits.

4. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

5. 1997Accenture

   Arbitration with Arthur Andersen begins

   Andersen Consulting files an arbitration claim with the International Chamber of Commerce, arguing that Arthur Andersen broke their agreement by building its own competing consulting practice.

6. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

7. 2000Accenture

   Arbitration ruling and Avanade

   In April 2000 Andersen Consulting and Microsoft form Avanade, a joint venture now majority owned by Accenture.

8. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

9. 2001Accenture

   Rename to Accenture and NYSE IPO

   Andersen Consulting becomes Accenture on Jan 1, 2001, a name based on "Accent on the future" suggested by an employee in Oslo. The Bermuda-incorporated company prices its IPO at $14.50 per share and starts trading on the NYSE on July 19, 2001.

10. 2004Accenture

    William D. Green becomes CEO

    William D. Green succeeds Joe Forehand as CEO on Sept 1, 2004; Forehand remains chairman.

11. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

12. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

13. 2009Accenture

    Reincorporation in Ireland

    On May 26, 2009 the board approves moving the company's place of incorporation from Bermuda to Ireland, which remains its legal domicile.

14. 2011Accenture

    Pierre Nanterme becomes CEO

    Pierre Nanterme becomes CEO in January 2011. The same year Accenture completes its purchase of insurance software company Duck Creek Technologies.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2013Accenture

    Fjord acquisition

    Accenture agrees in May 2013 to acquire Fjord, a service design consultancy, adding design capacity to Accenture Interactive.

17. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

18. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2016Accenture

    Duck Creek stake sold to Apax

    Funds advised by Apax Partners buy a 60% stake in Duck Creek Technologies from Accenture, which keeps 40%.

21. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

22. 2019Accenture

    CEO transition and Droga5

    Nanterme steps down for health reasons on Jan 11, 2019 and CFO David Rowland becomes interim CEO. Accenture Interactive completes the purchase of creative agency Droga5, and Julie Sweet becomes CEO on Sept 1, 2019.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2022Accenture

    Accenture Song

    On April 26, 2022 Accenture Interactive begins going to market as Accenture Song. FY2022 revenue rises 22% to $61.59B.

26. 2023Accenture

    $3B Data & AI investment

    In June 2023 Accenture announces a $3B investment over three years in its Data & AI practice and a plan to double AI talent to 80,000 people.

27. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

28. 2024Accenture

    Udacity acquisition

    Accenture completes its purchase of online education company Udacity on May 20, 2024 to support its Accenture LearnVantage training business.

29. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

30. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

31. 2025Accenture

    FY2025 results and restructuring

    FY2025 revenue reaches $69.67B with $80.62B in new bookings. In September 2025 Accenture outlines a six-month, $865M business optimization program, mainly severance, and moves to a single Reinvention Services unit.

32. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

33. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

34. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

35. 2026Accenture

    Faculty and Ookla deals

    Accenture completes the acquisition of UK AI company Faculty on March 16, 2026 and agrees in March 2026 to buy Ziff Davis's connectivity division (Ookla, Speedtest, Downdetector) for $1.2B in cash. Q3 FY2026 revenue is $18.72B.

36. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

37. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

38. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about Accenture vs AstraZeneca